Oct 2026
Clinical Outcomes of Ramucirumab Plus Taxane After Immune Checkpoint Inhibitor Therapy in HER2-negative Advanced Gastric Cancer
Although poor performance status was associated with worse survival, RAM plus taxane demonstrated meaningful antitumor activity, regardless of response to prior ICI-based treatment, suggesting that RAM plus taxane may warrant consideration as a treatment option in this setting.
Kazuhisa Yamaguchi, Yoshinori Kikuchi, Munehiro Wakabayashi et al.
· Anticancer Research · 0 citations